CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)

Detalles Bibliográficos
Main Authors:	Salisbury, E, McLaren, J, Jayne, D, Luqmani, R
Formato:	Journal article
Publicado:	2004

Títulos similares

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: Salisbury, E, et al.
Publicado: (2003)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
por: Salisbury, E, et al.
Publicado: (2003)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
por: McLaren, J, et al.
Publicado: (2003)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
por: McLaren, J, et al.
Publicado: (2004)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
por: McLaren, J, et al.
Publicado: (2001)

Cardiovascular outcomes in ANCA associated vasculitis
por: Mukhtyar, C, et al.
Publicado: (2008)

Explaining fatigue in ANCA-associated vasculitis.
por: Basu, N, et al.
Publicado: (2013)

Explaining fatigue in ANCA-associated vasculitis
por: Basu, N, et al.
Publicado: (2013)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
por: Basu, N, et al.
Publicado: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
por: Basu, N, et al.
Publicado: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis
por: Basu, N, et al.
Publicado: (2014)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
por: Basu, N, et al.
Publicado: (2012)

Diagnosis and management of ANCA associated vasculitis.
por: Berden, A, et al.
Publicado: (2012)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
por: McLaren, J, et al.
Publicado: (2000)

Markers for work disability in ANCA-associated vasculitis
por: Basu, N, et al.
Publicado: (2013)

Damage assessment in ANCA-associated vasculitis.
por: Bhamra, K, et al.
Publicado: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
por: Luqmani, R
Publicado: (2013)

Outcome measures in ANCA-associated vasculitis.
por: Suppiah, R, et al.
Publicado: (2010)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
por: Luqmani, R
Publicado: (2013)

Cutaneous manifestations of ANCA-associated vasculitis
por: Chiesafuxench, Z, et al.
Publicado: (2016)

Predictors of renal involvement in ANCA associated vasculitis
por: Kronbichler, A, et al.
Publicado: (2018)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
por: Suppiah, R, et al.
Publicado: (2011)

Research advances on the impact of environmental risk factors on the incidence of ANCA-associated vasculitis
por: Min-min Xiao, et al.
Publicado: (2023-10-01)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
por: Suppiah, R, et al.
Publicado: (2011)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
por: Luqmani, R, et al.
Publicado: (2007)

Long-term survival of ANCA-associated vasculitis
por: Flossmann, O, et al.
Publicado: (2009)

Thrombosis risk factors in ANCA-associated vasculitis
por: E. N. Kharlamova, et al.
Publicado: (2023-04-01)

Diagnosis and assessment of systemic vasculitis.
por: McLaren, J, et al.
Publicado: (2002)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
por: Suppiah, R, et al.
Publicado: (2011)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
por: Luqmani, R, et al.
Publicado: (1999)

Comparison of disease activity measures for ANCA-associated vasculitis.
por: Merkel, P, et al.
Publicado: (2004)

ANCA-associated vasculitis: Where can we go from here?
por: Luqmani, R
Publicado: (2010)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
por: Yew, S, et al.
Publicado: (2012)

ANCA Associated Vasculitis Subtypes: Response [Letter]
por: Merkel PA, et al.
Publicado: (2022-09-01)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
por: Jones, R, et al.
Publicado: (2010)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
por: Ntatsaki, E, et al.
Publicado: (2014)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
por: Arnold, D, et al.
Publicado: (2010)

Environmental factors influencing the risk of ANCA-associated vasculitis
por: Wen-Man Zhao, et al.
Publicado: (2022-09-01)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
por: Lapraik, C, et al.
Publicado: (2007)